KRSA-028 / Korsana Biosciences - LARVOL DELTA

Design and characterization of KRSA-028, a novel bispecific antibody targeting amyloid beta and transferrin receptor with selective effector function modulation (CTAD 2026) - No abstract available

Bispecific

Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement (Businesswire) - "Upon completion of the transaction, the combined company plans to operate under the name Korsana Biosciences, Inc. and trade on Nasdaq under the ticker symbol 'KRSA'. In support of the proposed merger, Korsana has secured commitments for an oversubscribed private investment that is expected to result in total gross proceeds of approximately $380 million from a syndicate of investors....The combined company’s cash and cash equivalents balance at closing...is anticipated to fund Korsana’s operations into 2029 and provides runway through key clinical milestones. These include the advancement of KRSA-028 through Phase 1 healthy volunteer data expected in mid-2027 and interim proof of concept data measuring amyloid plaque clearance in Alzheimer’s patients expected by the end of 2027."

Commercial • P1 data • Alzheimer's Disease

A new entrant in the race to shepherd antibodies for Alzheimer’s disease across the blood-brain barrier has emerged. Korsana Biosciences has catapulted out of stealth with $175 million and designs for a 2027 clinical debut. (FierceBiotech) - "Korsana’s lead Alzheimer’s candidate, KRSA-028, was discovered in partnership with Paragon Therapeutics, a protein-engineering specialist...Korsana plans to bring KRSA-028 into the clinic in early 2027, with initial safety data reading out in the middle of the year and proof-of-concept evidence that the antibody can eliminate amyloid plaques by the end of the year, Violin told Fierce Biotech in an interview."

Clinical data • Licensing / partnership • New trial • Alzheimer's Disease

EIR Biopharma is hoping to bring in $17.1 million from an IPO on the New York Stock Exchange that could fund development of its preclinical eye disease drug. (FierceBiotech) - "The biotech has earmarked $2 million of the proceeds to take EIR-1003, its lead drug for eye conditions like glaucoma, diabetic retinopathy and uveal melanoma, through preclinical development. Another $5 million will be set aside to bankroll phase 1/1b clinical trials, which are penciled in for 2027, EIR explained in the filing."

Financing • New P1 trial • Diabetic Retinopathy • Glaucoma • Uveal Melanoma